Your session is about to expire
← Back to Search
Immunotherapy for Smoldering Multiple Myeloma
Study Summary
This trial is testing pembrolizumab to treat slow growing multiple myeloma. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a serious autoimmune disease that needed strong medication in the last 2 years.You have another cancer that is currently getting worse or is still active.You have a history of needing steroids for lung inflammation or currently have lung inflammation.You have signs of lung disease.You have an ongoing infection that needs treatment with medication throughout your body.Adults with a certain type of smoldering multiple myeloma that is at intermediate or high risk.Your SMM diagnosis is confirmed by specific medical criteria from the Mayo clinic, PETHEMA, or SWOG.You have a history of HIV or active hepatitis B or C.Your kidneys work well enough to filter out waste from your blood.You are able to perform daily activities without any problems or with only slight limitations.Your body has enough infection-fighting white blood cells.Your hemoglobin level is at least 10 grams per deciliter.You have mental health or drug problems that could affect your ability to participate in the trial.Your platelet count is at least 50 billion per liter.Your bilirubin levels are within a certain range considered normal.Your AST and ALT levels should be less than 3 times the upper limit of normal.You have a type of cancer called plasma cell leukemia.You have tuberculosis that is currently active.You have health conditions, ongoing treatments, or abnormal test results that could affect the trial outcomes.You have received treatment with a specific type of medication that targets the PD-1, PD-L1, or PD-L2 proteins before.You are allergic to pembrolizumab or any of its ingredients.There are signs that you have a specific disease called myeloma or other markers showing a possible cancer.You have received or are currently receiving systemic treatment for smoldering multiple myeloma.You have a weakened immune system or have been taking steroids for a week before the trial.
- Group 1: Treatment (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What types of illnesses has Pembrolizumab been employed to address?
"Pembrolizumab is commonly used to treat a variety of malignant tumors, including those which are unresectable and exhibit microsatellite instability high. It can also be used as an adjuvant therapy following chemotherapy."
Has Pembrolizumab been tested in any other clinical investigations?
"Currently, there are 962 active studies involving Pembrolizumab and 122 of them are in the advanced Phase 3 stage. Most trials for this medication occur in Houston, Texas; however, it can be accessed at 35765 different medical centres globally."
Are patients currently able to enroll in this research endeavor?
"This research project is not presently recruiting patients. It was first posted on 7/20/2016 and last revised on 3/23/2022. If you are looking for other trials, 808 studies related to multiple myeloma and 962 involving Pembrolizumab have open enrolment slots currently available."
Share this study with friends
Copy Link
Messenger